Avita Medical, Inc. (RCEL)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1762303 · fiscal year ends in Dec
Closing price $16.68 on 29 Oct 2026; 52-week range $3.27 to $16.68.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $75.6M
- Revenue growth
- 1.0%
- Net income, last twelve months
- -$43.1M
- Earnings per share
- -$1.44
- Gross margin
- 81.6%
- Operating margin
- -46.6%
- Net margin
- -57.0%
- Market value
- $515.7M
- Cash
- $9.1M
- Debt
- $46.7M
- Shares outstanding
- 30.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $71.6M | -$42.5M | -$48.6M | -$1.74 | -$32.2M | 10-K filed 12 Feb 2026 |
| FY2024 | 31 Dec 2024 | $64.3M | -$56.6M | -$61.8M | -$2.39 | -$58.1M | 10-K filed 13 Feb 2025 |
| FY2023 | 31 Dec 2023 | $50.1M | -$42.7M | -$35.4M | $1.40 | -$39.4M | 10-K filed 22 Feb 2024 |
| FY2022 | 31 Dec 2022 | $34.4M | -$27.5M | -$26.7M | $1.07 | -$19.5M | 10-K filed 23 Feb 2023 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $21.7M | -$7.7M | -$0.25 |
| Q1 FY2026 | 31 Mar 2026 | $19.3M | -$10.6M | -$0.35 |
| Q4 FY2025 | 31 Dec 2025 | $17.6M | -$11.6M | -$0.38 |
| Q3 FY2025 | 30 Sep 2025 | $17.1M | -$13.2M | -$0.46 |
| Q2 FY2025 | 30 Jun 2025 | $18.4M | -$9.9M | -$0.38 |
| Q1 FY2025 | 31 Mar 2025 | $18.5M | -$13.9M | -$0.53 |
| Q4 FY2024 | 31 Dec 2024 | $18.4M | -$11.6M | -$0.44 |
| Q3 FY2024 | 30 Sep 2024 | $19.5M | -$16.2M | -$0.62 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $68.8M | 96.1% |
| Japan | $2.1M | 2.9% |
| United Kingdom | $486.0K | 0.7% |
| Australia | $200.0K | 0.3% |
| European Union | $49.0K | 0.1% |
Company events
The newest 8-K filings of 107 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 11 Aug 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 6 Aug 2026 | 8-K/A | Shareholder vote | 5.07 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 8 Jun 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 4 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 1 May 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 12 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Jan 2026 | 8-K | Results, Material agreement, Agreement ended, New debt, Share sale | 1.01, 1.02, 2.02, 2.03, 3.02, 9.01 |
| 5 Jan 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 6 Nov 2025 | 8-K | Results, Material agreement | 1.01, 2.02, 9.01 |
| 17 Oct 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 216 held.
| Filed | Form | Period |
|---|---|---|
| 25 Aug 2026 | S-8 | – |
| 11 Aug 2026 | 8-K | 5 Aug 2026 |
| 6 Aug 2026 | 8-K/A | 3 Jun 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 8 Jun 2026 | 8-K | 5 Jun 2026 |
| 4 Jun 2026 | 8-K | 3 Jun 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 1 May 2026 | 8-K | 30 Apr 2026 |
| 22 Apr 2026 | DEF 14A | 22 Apr 2026 |
| 9 Apr 2026 | EFFECT | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 9 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,200 | $4.00 | $20.8K | 107,961 | 10 Jun 2026 |
| 9 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.20 | $21.0K | 97,761 | 9 Jun 2026 |
| 9 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.18 | $20.9K | 102,761 | 9 Jun 2026 |
| 3 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.10 | $20.5K | 87,761 | 5 Jun 2026 |
| 3 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.09 | $20.4K | 92,761 | 5 Jun 2026 |
| 2 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.18 | $20.9K | 15,000 | 3 Jun 2026 |
| 2 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.21 | $21.0K | 20,000 | 3 Jun 2026 |
| 1 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.34 | $21.7K | 5,000 | 3 Jun 2026 |
| 1 Jun 2026 | Woody Joseph Fralin, Director | Purchase | 5,000 | $4.26 | $21.3K | 10,000 | 3 Jun 2026 |
| 20 May 2026 | O'Toole David D, CFO | Purchase | 2,000 | $4.26 | $8.5K | 145,927 | 20 May 2026 |
| 19 May 2026 | O'Toole David D, CFO | Purchase | 2,000 | $4.24 | $8.5K | 143,927 | 19 May 2026 |
| 11 Mar 2026 | O'Toole David D, CFO | Purchase | 1,800 | $4.78 | $8.6K | 141,927 | 11 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 30 Jan 2026 | The Vanguard Group | 13G amended | 4.73% | 1.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.8M | -1.8% | 7.63 |
| 30 Sep 2026 | 2.9M | +0.08% | 9.2 |
| 15 Sep 2026 | 2.9M | -1.78% | 10.54 |
| 31 Aug 2026 | 2.9M | +6.89% | 6.93 |
| 14 Aug 2026 | 2.7M | +5.41% | 2.5 |
| 31 Jul 2026 | 2.6M | -0.37% | 11.1 |
| 15 Jul 2026 | 2.6M | +3.45% | 7.75 |
| 30 Jun 2026 | 2.5M | -21.52% | 6 |
Funds that hold it
From each fund's latest Form 13F.
97 funds held it at 30 Jun 2026: 45 added and 20 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Vanguard Capital Management LLC | 1,333,914 | $5.5M | -1,238 |
| BlackRock, Inc. | 564,952 | $2.3M | -568,174 |
| Geode Capital Management, LLC | 339,822 | $1.4M | -203,152 |
| Marshall Wace, LLP | 338,387 | $1.4M | +285,825 |
| AQR Capital Management LLC | 321,013 | $1.3M | +226,652 |
| Morgan Stanley | 200,462 | $827.9K | +42,841 |
| Vanguard Fiduciary Trust Co. | 182,402 | $753.3K | -11,034 |
| NewEdge Advisors, LLC | 148,931 | $615.1K | +62,046 |
| Macquarie Group Ltd | 144,164 | $595.4K | +132,262 |
| State Street Corp. | 128,977 | $532.7K | -300,045 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B